UBS Group
BCAX

UBS Group’s Bicara Therapeutics BCAX Stock Holding History

UBS Group’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.96M Sell
65,986
-113,505
-63% -$2.53M ﹤0.01% 5128
2026
Q1 		$3.57M Sell
179,491
-12,700
-7% -$219K ﹤0.01% 4417
2025
Q4 		$3.23M Buy
192,191
+94,829
+97% +$1.62M ﹤0.01% 4478
2025
Q3 		$1.54M Buy
97,362
+9,756
+11% +$109K ﹤0.01% 5209
2025
Q2 		$814K Buy
87,606
+21,752
+33% +$259K ﹤0.01% 5614
2025
Q1 		$858K Sell
65,854
-134,553
-67% -$1.79M ﹤0.01% 5415
2024
Q4 		$3.49M Buy
200,407
+197,617
+7,083% +$4.11M ﹤0.01% 4186
2024
Q3 		$71.1K Buy
+2,790
New +$71.2K ﹤0.01% 6588

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group's BCAX Position: Q2 2026 in Review

UBS Group reduced its Bicara Therapeutics (BCAX) stake by 63% in Q2 2026, selling an estimated $2.53M and leaving 65,986 shares worth $1.96M. The position accounts for ﹤0.01% of the portfolio, ranked #5128.

UBS Group first reported a position in BCAX in Q3 2024 and has held it in 8 quarters since. The position peaked at $3.57M in Q1 2026. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • UBS Group held 65,986 shares of Bicara Therapeutics worth $1.96M as of Q2 2026.
  • UBS Group sold 113,505 Bicara Therapeutics shares in Q2 2026, an estimated $2.53M.
  • Bicara Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5128 holding.
  • UBS Group first reported a position in Bicara Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • UBS Group's Bicara Therapeutics position peaked at $3.57M in Q1 2026.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.